Investor Presentaiton
R&D efforts align with ESG values
Addressing areas of high
unmet need
• 40+ disease areas studied,
including several rare diseases
Novel drugs with three first-in-class
medicines launched in 2022
Diverse modalities with 10 drug
platforms (e.g., cell therapy)
Enhancing health equity and
clinical trial diversity
Numerous initiatives related to
ensuring clinical trial diversity:
58% of US clinical trial sites
located in highly diverse
communities
Racial diverse participants at 22%
(goal 20%) in 2022
Responsibly driving innovation
to maximize impact
"Green by design" principles and a
green chemistry approach,
reducing total waste generated
⚫ "Green chemistry reviews" to
identify opportunities for reducing
safety and environmental impact
Il Bristol Myers Squibb™ Representative examples, not exhaustive
Not for Product Promotional Use 146View entire presentation